From Stat

A Court Struck Down a Ban on Pharma ‘Price Gouging.’ One State Wants to Revive It — and Others Could Follow

January 16, 2020

In one of their first acts of 2020, state lawmakers will attempt to bring a vanquished bill back from the dead.

Lawmakers in New Hampshire next month are set to consider a proposed ban on generic drug “price gouging” — the latest in a series of attempts by statehouses to tackle prescription drug costs. But as most state legislatures around the country pursue new, aggressive ideas to lower drug prices, the Granite State is revisiting a bill largely left for dead after a federal court struck down Maryland’s version two years ago….

In one of their first acts of 2020, state lawmakers will attempt to bring a vanquished bill back from the dead.

Lawmakers in New Hampshire next month are set to consider a proposed ban on generic drug “price gouging” — the latest in a series of attempts by statehouses to tackle prescription drug costs. But as most state legislatures around the country pursue new, aggressive ideas to lower drug prices, the Granite State is revisiting a bill largely left for dead after a federal court struck down Maryland’s version two years ago….

Read the full Stat+ article

The Ghosts of JPMs Past: How 20 Years of Deals, Scandal, and Science Have Shaped Health Care

January 9, 2020

Biotech is celebrating a platinum anniversary next week: 20 years since J.P. Morgan took over the industry’s biggest conference, an annual ritual of brokered mergers, broken promises, and breakthrough science.

The J.P. Morgan Healthcare Conference is more than a venue for deals. It’s a place where fierce arguments break out, where industry memes get made, and where biotech examines its warts and wrinkles.

Biotech is celebrating a platinum anniversary next week: 20 years since J.P. Morgan took over the industry’s biggest conference, an annual ritual of brokered mergers, broken promises, and breakthrough science.

The J.P. Morgan Healthcare Conference is more than a venue for deals. It’s a place where fierce arguments break out, where industry memes get made, and where biotech examines its warts and wrinkles.

With that in mind, STAT decided to look back at the record. What emerged was not just a series of recollections about a conference, but the history of an industry, chock-full of lessons about management, leadership, and communication. Over the past two decades, many of the biggest heroes and villains in the pharmaceutical industry have graced the stages of the Westin St. Francis Hotel in San Francisco, where the conference has been held since it began 38 years ago under the auspices of Hambrecht & Quist, a now largely forgotten investment bank….

Read the full Stat article

One Drug Maker Has A Lot More to Lose Than Others, Under Early Drafts of Drug Importation Plans

December 19, 2019

President Trump’s plan to let states and drug wholesalers import medicines from Canada doesn’t apply to every single drug in the same way — and early indications suggest some drug makers have far more to lose than others.

On Wednesday, the Trump administration began a long, regulatory march toward eventually allowing states to import drugs from Canada.

President Trump’s plan to let states and drug wholesalers import medicines from Canada doesn’t apply to every single drug in the same way — and early indications suggest some drug makers have far more to lose than others.

On Wednesday, the Trump administration began a long, regulatory march toward eventually allowing states to import drugs from Canada. While the implementation of that policy is likely to take months, if not years, four states have already passed laws directing their state administrations to submit importation plans to HHS for eventual approval. One state, Florida, has already submitted a plan, and Colorado released an early draft of its plan last month….

Read the full Stat+ article

What Side Effects? Problems With Medicines May Be Vastly Underreported to the FDA

December 4, 2019

It’s no secret that the many side effects caused by medicines do not get reported to the Food and Drug Administration, but a new report suggests the magnitude of underreporting is far greater than imagined.

After examining side effects that were conveyed to the regulator for five widely used medicines — two different types of arthritis treatments, an antipsychotic, and a blood thinner — just 1% of an estimated 276,000 serious adverse events had been reported in 2017.

It’s no secret that the many side effects caused by medicines do not get reported to the Food and Drug Administration, but a new report suggests the magnitude of underreporting is far greater than imagined.

After examining side effects that were conveyed to the regulator for five widely used medicines — two different types of arthritis treatments, an antipsychotic, and a blood thinner — just 1% of an estimated 276,000 serious adverse events had been reported in 2017….

Read the full Stat article

Democrats Still Have Questions About Nancy Pelosi’s Drug Pricing Plan

September 19, 2019

For months, Nancy Pelosi has kept even her fellow Democrats in the dark on her plan to lower drug prices.

The big reveal, for the lawmakers, came this week: Pelosi barnstormed the Capitol as if campaigning for office, pitching moderate, progressive, and middle-ground Democratic groups on her plan. But for many members of Congress, Pelosi’s presentation left more to be desired — even as she’s expected to publicly release it as soon as today.

For months, Nancy Pelosi has kept even her fellow Democrats in the dark on her plan to lower drug prices.

The big reveal, for the lawmakers, came this week: Pelosi barnstormed the Capitol as if campaigning for office, pitching moderate, progressive, and middle-ground Democratic groups on her plan. But for many members of Congress, Pelosi’s presentation left more to be desired — even as she’s expected to publicly release it as soon as today.

“[There are] an awful lot of questions, which is natural at this point,” said Rep. Joe Kennedy (D-Mass.), a member of the House Energy and Commerce Committee. “I think we would benefit from seeing some more details….”

Read the full Stat article